| 09.09 22:43 | dpa-AFX: *GERON CORP. APPOINTS JIM ZIEGLER AS CHIEF COMMERCIAL OFFICER |
| 08.08 13:18 | dpa-AFX: Geron Corporation Q2 Loss Rises |
| 08.08 13:12 | dpa-AFX: *GERON CORP. Q2 OPERATING LOSS $69.33 MLN VS. LOSS $51.95 MLN LAST YEAR |
| 08.08 13:12 | dpa-AFX: *GERON CORP. Q2 NET LOSS $67.38 MLN VS. NET LOSS $49.23 MLN LAST YEAR |
| 08.08 13:12 | dpa-AFX: *GERON CORP. Q2 REVENUES $882K VS. $29K LAST YEAR |
| 08.08 13:06 | dpa-AFX: *GERON CORP. Q2 NET LOSS/SHR $0.10 VS. LOSS/SHR $0.09 LAST YEAR |
| 08.08 13:01 | dpa-AFX: Geron Q2 24 Earnings Conference Call At 8:00 AM ET |
| 26.07 13:35 | dpa-AFX: *GERON ANNOUNCES NCCN GUIDELINES UPDATE RECOMMENDING RYTELO FOR SYMPTOMATIC ANEMIA IN LOWER-RISK MDS |
| 11.06 08:20 | dpa-AFX: *BARCLAYS STARTET GERON CORP MIT 'OVERWEIGHT' - ZIEL 9 USD |
| 11.06 08:20 | dpa-AFX: *BARCLAYS STARTS GERON CORP WITH 'OVERWEIGHT' - PRICE TARGET 9 USD |
| 07.06 17:40 | dpa-AFX: Geron Shares Rise After Rytelo Gets FDA Approval For Treatment Of Lower-risk MDS With TD Anemia |
| 07.06 13:59 | dpa-AFX: *GERON VORBÖRSLICH +22% - FDA ERTEILT ZULASSUNG FÜR RYTELO GEGEN BLUTKRANKHEITEN |
| 07.06 13:06 | dpa-AFX: Pre-market Movers: VERO, VS, BMEA, GME, VRAX. |
| 07.06 04:18 | dpa-AFX: FDA Approves Geron's Rytelo For Treatment Of Lower-Risk MDS Anemia |
| 02.05 13:23 | dpa-AFX: Geron Corporation Q1 Loss increases, but beats estimates |
| 02.05 13:18 | dpa-AFX: *GERON Q1 REVENUES $304,000 VS $21,000 PRIOR YEAR |
| 02.05 13:07 | dpa-AFX: *GERON Q1 NET LOSS WIDENS TO $55.4 MLN OR $0.09/SHR FROM $38.1 MLN OR $0.07/SHR PRIOR YEAR |
| 10.04 15:16 | dpa-AFX: Geron To Present At Needham Virtual Healthcare Conference; Webcast At 10:15 AM ET |
| 19.03 14:34 | dpa-AFX: Geron Announces Pricing Of $150 Mln Underwritten Offering Of Common Stock, Pre-Funded Warrants |
| 19.03 14:10 | dpa-AFX: *GERON ANNOUNCES PRICING OF $150 MLN UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS |
|
|
